[1] OESTREICH J H, BEST L G, DOBESH P P. Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans[J]. Am Heart J,2014,167(3):413-418. doi:  10.1016/j.ahj.2013.10.028
[2] TANTRAY J A, REDDY K P, JAMIL K, et al. Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy[J]. Int J Cardiol,2017,229:113-118. doi:  10.1016/j.ijcard.2016.11.217
[3] XIE X, MA Y T, YANG Y N, et al. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population[J]. PLoS One,2013,8(3):e59344. doi:  10.1371/journal.pone.0059344
[4] ZOU J J, XIE H G, CHEN S L, et al. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention[J]. Eur J Clin Pharmacol,2013,69(4):771-777. doi:  10.1007/s00228-012-1392-5
[5] REHMAN K U, AKHTAR T, SABAR M F, et al. Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients[J]. Exp Ther Med,2015,10(1):309-315. doi:  10.3892/etm.2015.2493
[6] ARADI D, KOMÓCSI A. Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS? Platelets,2012,23(3):167-176. doi:  10.3109/09537104.2011.610475
[7] 周健, 吕虹, 康熙雄. 中国汉族人群不同性别、年龄、体重指数之间细胞色素氧化酶CYP2C19基因多态性的检测[J]. 中国临床药理学与治疗学, 2007, 12(2):208-213. doi:  10.3969/j.issn.1009-2501.2007.02.018
[8] 侯文洁, 张亮, 丁红梓, 等. 硫酸氢氯吡格雷片在PCI术后患者体内的药动学研究[J]. 现代药物与临床, 2018, 33(3):451-455.
[9] 曹津津, 周秋云, 钱智磊, 等. 利用基因检测技术指导氯吡格雷的合理应用[J]. 药学与临床研究, 2017, 25(3):251-252.
[10] HELD C, ASENBLAD N, BASSAND J P, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial[J]. J Am Coll Cardiol,2011,57(6):672-684. doi:  10.1016/j.jacc.2010.10.029
[11] JIA D M, CHEN Z B, ZHANG M J, et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China[J]. Stroke,2013,44(6):1717-1719. doi:  10.1161/STROKEAHA.113.000823
[12] SNOEP J D, HOVENS M M, EIKENBOOM J C, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis[J]. Am Heart J,2007,154(2):221-231. doi:  10.1016/j.ahj.2007.04.014